At a glance
- Sermorelin was approved by the FDA (Geref, December 28, 1990), but the products are no longer marketed.
- PubMed lists 35 publications mentioning it, including 1 randomized controlled trial and 0 animal-only studies.
- ClinicalTrials.gov lists 27 registered studies testing it (1 active).
- FDA's adverse event system (FAERS) holds 59 reports mentioning it; 36 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| NDA019863 | GEREF | Approved, discontinued | December 28, 1990 | EMD SERONO |
| NDA020443 | GEREF | Approved, discontinued | September 26, 1997 | EMD SERONO INC |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review.
- Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report.
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
- A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
- Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
- Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.
- Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.
- In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 27
- Active
- 1
- With posted results
- 11
Conditions studied
Show 17 more studies
All 27 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 59
- Serious
- 36
- With death outcome
- 1
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.